CA2307632C - Aqueous liquid pharmaceutical composition - Google Patents

Aqueous liquid pharmaceutical composition Download PDF

Info

Publication number
CA2307632C
CA2307632C CA002307632A CA2307632A CA2307632C CA 2307632 C CA2307632 C CA 2307632C CA 002307632 A CA002307632 A CA 002307632A CA 2307632 A CA2307632 A CA 2307632A CA 2307632 C CA2307632 C CA 2307632C
Authority
CA
Canada
Prior art keywords
gatifloxacin
aqueous liquid
disodium edetate
pharmaceutical composition
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002307632A
Other languages
French (fr)
Other versions
CA2307632A1 (en
Inventor
Shinichi Yasueda
Katsuhiro Inada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16986030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2307632(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharmaceutical Co Ltd, Kyorin Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of CA2307632A1 publication Critical patent/CA2307632A1/en
Application granted granted Critical
Publication of CA2307632C publication Critical patent/CA2307632C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature:
(~)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.

Description

DESCRIPTION
AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION
FIELD OF THE INVENTION

The present invention relates to an aqueous liquid pharmaceutical composition comprising as a main component a quinolone carboxylic acid derivative, Gatifloxacin (chemical nomenclature: ( )-1-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-(3-methyl-l-piperazinyl)-4-oxo-3-quinoline carboxylic acid). Further, the present invention relates to a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin.

BACKGROUND OF THE INVENTION

Gatifloxacin is a new quinolone antimicrobial agent which is recognized to exhibit a strong antimicrobial activity against not only Gram-negative bacteria but also Gram-positive bacteria, anaerobes and mycoplasmas. Then, it has been proposed to apply it to ophthalmological infectious diseases such as conjunctivitis, dacryocystitis, hordeolum etc. and otorhinological infectious diseases such as otitis externa, otitis media, sinusitis etc (see JP-B 8-9597).
For designing a pharmaceutical preparation in the form of eye drops containing an antimicrobial agent, an index is to raise corneal permeability of the agent to increase the amount of the agent to transfer to aqueous humor. However, in general, the agent applied to eyes can scarcely pass into inside of the eyes because of dilution with tears and the barrier function of corneas. Then, as a method of improving corneal permeability of the agent, a method using an absorption enhancer has been proposed. In addition, a method using a viscous base material has been proposed to increase the agent-retentivity at the anterior ocular segment.

OBJECTS OF THE INVENTION

With regard to Gatifloxacin, although its application to ophthalmological or otorhinological infectious diseases has been proposed, there is no report about a study of an aqueous liquid pharmaceutical composition thereof for topical administration, which can be actually applied to eyes, for example, its passing into inside of eyes, stability, etc.

In view of these circumstances, an object of the present invention is to permit actual application of Gatifloxacin in ophthalmological or otorhinological field, in particular, to provide an aqueous liquid pharmaceutical composition comprising as an effective component Gatifloxacin.
SUMMARY OF THE INVENTION

The present inventors have intensively studied to apply Gatifloxacin in ophthalmological field and, consequently, have found that this objective can be achieved by coexistence of Gatifloxacin with disodium edetate.

Disodium edetate is considered to lower the calcium concentration in corneal epithelium cells and expanding intercellular spaces, thereby accelerating passing of a water-soluble medicament into inside of eyes. However, a rise in corneal permeability of a medicament depends on a concentration of disodium edetate (Journal of Pharmaceutical Science, 77: 3-14, 1988) and, normally, at present, disodium edetate should be used at a high concentration as much as0.5g (Investigative Ophthalmology & Visual Science, 2-E:110-113, 1985; Experimental Eye Research, 54: 747-757, 1992; Pharmaceutical Research, 12: 1146-1150). Nevertheless, the present inventors have found that corneal permeability of Gatifloxacin can be improved at a lower concentration of disodium edetate.

Further, it has been known that the solubility of Gatifloxacin depends on pH and its solubility at about physiological pH is very low. Then, in order to dissolve a sufficient amount of Gatifloxacin in an aqueous liquid pharmaceutical composition, pH of the composition should be adjusted to an acidic or alkaline range, which causes a problem such as irritation upon topical administration. However, the present inventors also have found that the solubility of Gatifloxacin at about physiological pH is improved by coexistence thereof with disodium edetate.

The present invention has been completed based on these present inventors' novel findings and, according to the present invention, there is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin or its salt and disodium edetate. In particular, the aqueous liquid pharmaceutical composition of the present invention is an aqueous solution containing Gatifloxacin or its salt and disodium edetate.
Further, the present invention provides a method for raising corneal permeability of Gatifloxacin which comprises incorporating disodium edetate into eye drops containing Gatifloxacin or its salt; a method for preventing precipitation of Gatifloxacin crystals which comprises incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt; and a method for preventing coloration of Gatifloxacin which comprises incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.

This object as well as other objects and advantages of the present invention will become apparent to those skilled in the art from the following description.

DETAILED DESCRIPTION OF THE INVENTION

In the present invention, Gatifloxacin or its salt is used as the effective component. Examples of the salt of Gatifloxacin used in the present invention include those with 5 inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc.; those with organic acids such as methanesulfonic acid, lactic acid, oxalic acid, acetic acid, etc.;
or those with sodium, potassium, magnesium, calcium, aluminum, cerium, chromium, cobalt, copper, iron, zinc, platinum, silver, etc.

Normally, the amount of Gatifloxacin or its salt (hereinafter sometimes simply referred to as "Gatifloxacin") to be formulated in the aqueous liquid pharmaceutical composition of the present invention is varied according to the degree of infection of a particular subject, but normally, Gatifloxacin is formulated within the range of 0.1 to 1.0 w/v%, preferably 0.1 to 0.8 w/v%, more preferably 0.3 to 0.5 w/v%.

Normally, disodium edetate is formulated in an amount of 0.001 to 0.2 w/v%, preferably 0.005 to 0.1 w/v%, more preferably 0.01 to 0.1 w/v%.

Normally, the aqueous liquid pharmaceutical composition of the present invention is adjusted to pH 5 to 8, preferably pH
5.5 to 7.5, more preferably pH 6 to 7.

If necessary, the aqueous liquid pharmaceutical composition of the present invention may further contain appropriate additives, for example, an isotonic agent (e.g., sodium chloride, potassium chloride, boric acid, glycerin, propylene glycol, mannitol, sorbitol, glucose etc.); a buffer solution (e.g., phosphate buffer solution, acetate butter solution, borate buffer solution, citrate buffer solution, glutamic acid,F -aminocapronic acid, etc.); a preservative (e.g., benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, p-hydroxybenzoate, etc.), a thickening agent (e.g., methylcellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, sodium hyaluronate, carboxyvinyl polymer, polyvinyl alcohol, polyvinyl pyrrolidone, Macrogol (polyethylene glycol), etc.), a pH adjusting agent (e.g., hydrochloric acid, sodium hydroxide, acetic acid, phosphoric acid, etc.), and the like.

The aqueous liquid pharmaceutical composition of the present invention can be produced by a per se known method. For example, it can be produced by the process described in the section of "Ophthalmic Solutions" or "Liquids and Solutions", General Rules for Preparations, The Japanese Pharmacopoeia Thirteenth Edition.
The aqueous liquid pharmaceutical composition of the present invention has antimicrobial activity and can be used for prophylaxis and therapy of blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsitis, keratitis, corneal ulcer, postoperative infection, and the like. For this purpose, the composition can be instilled in the eye about three times a day at a dosage of one drop per once. For otitis externa or otitis media, normally, the composition can be instilled in the ear twice a day at a dosage of 6 to 10 drops per once. Further, for sinusitis, normally, the composition can be sprayed and inhaled three times every other day in a week at a dosage of 2 to 4 ml per once, or can be administered in the maxillary sinus once a week at a dosage of 1 ml per once.

The dosage can be increased or decreased according to the degree of a particular disease condition.

The present invention will be further illustrated by the following experiments and examples, but the present invention is not limited thereto.

Experiment 1 Effect of disodium edetate on transfer of Gatifloxacin to aqueous humor Method According to the formulations of Table l, eye drops of Gatifloxacin were prepared (formulations A-C). Each of the eye drops (50 ul/eye) was instilled once in the eyes of male Japanese albino rabbits (body weight: about 2 kg). At one hour after the instillation, the aqueous humor was collected and the Gatifloxacin concentration was determined by HPLC.
Table 1 Formulations A B C
Gatifloxacin 0.5 g 0.5 g 0.5 g Disodium edetate - - 0.05 g Sodium chloride 0.9 g 0.9 g 0.9 g Hydrochloric acid q.s. q.s. q.s.
Sodium hydroxide q.s. q.s. q.s.
Sterilized purified water to total to total to total 100 ml 100 ml 100 ml pH 7.0 6.0 6.0 Results The concentration of Gatifloxacin in the aqueous humor at one hour after the instillation is shown in Table 2.

When pH dropped, the amount of Gatifloxacin transferred to the aqueous humor decreased. For the formulation adjusted to pH 6.0 (formulation C), the amount of Gatifloxacin transferred to the aqueous humor increased by about 1.2 times and 1.5 times as much as those of the formulations A (pH 7.0) and B (pH 6.0) which were used as controls, respectively.

Since the concentration of disodium edetate normally used for raising corneal permeability is 0.5 w/v%, these results show that corneal permeability of Gatifloxacin has been improved even by using disodium edetate in 1/10 amount as much as that normally used.
Table 2 Formulations Gatifloxacin concentration in aqueous humor ( g/ml) A 1.61 0.43 B 1.30 0.42 C 1.93 0.95 Experiment 2 Effect of disodium edetate on precipitation of Gatifloxacin crystals Method According to the formulations of Table 3, aqueous liquid preparations of Gatifloxacin were prepared (formulations B-D).

Each solution was filled in 5 ml glass ampoules. The ampoules were subjected to freezing at -30 C (overnight) and then thawing at room temperature repeatedly to observe precipitation of Gatifloxacin crystals.

Table 3 Formulations B C D
Gatifloxacin 0.5 g 0.5 g 0.5 g Disodium edetate - 0.05 g 0.1 g Sodium chloride 0.9 g 0.9 g 0.9 g Hydrochloric acid q.s. q.s. q.s.
Sodium hydroxide q.s. q.s. q.s.
Sterilized purified water to total to total to total 100 ml 100 ml 100 ml pH 6.0 6.0 6.0 Results In the formulation in which disodium edetate was not formulated (formulation B), crystals were precipitated when freezing and thawing were repeated twice to three times. On the other hand, when disodium edetate was formulated (formulations C
and D), no precipitation of crystals was recognized even when freezing and thawing were repeated ten times.

5 These results show that precipitation of Gatifloxacin crystals under storage conditions at a low temperature is prevented by formulating disodium edetate in an aqueous liquid preparation of Gatifloxacin.

Experiment 3 10 Effect of disodium edetate on preventing coloration of Gatifloxacin Method Sodium chloride (0.86 g) and 0.1 mol/liter hydrochloric acid (5.2 ml) were added to sterilized purified water (80 ml) in a stainless steel (SUS316) beaker of 8 cm diameter and the mixture was stirred. Then, Gatifloxacin (0.32 g) and disodium edetate (at a final concentration of 0%, 0.001%, 0.005%, 0.01% or 0.05%) were added thereto and dissolved therein. The solution was adjusted to pH 6.5 with 0.1 mol/liter sodium hydroxide and the total volume was made up to 100 ml to obtain an aqueous liquid preparation of Gatifloxacin. A color difference between the aqueous liquid preparation and sterilized purified water was determined with a differential colorimeter (Chroma meter CT-210C manufactured by Minolta, light source Lab table system) . As a control, an aqueous liquid preparation of Gatifloxacin prepared in a glass beaker was used.

Results The color difference determined is shown in Table 4.
The aqueous liquid preparation prepared in the glass beaker and used as the control had the color difference of 1.9 to 2.0 and a pale yellow color. On the other hand, the aqueous liquid preparation prepared in the stainless steel beaker had the color difference of 3.17 in case that disodium edetate was not added and 2.42 in case that 0.01% of disodium edetate was added. They had a light yellow color and a pale yellow color, respectively. Thus, they were discolored by formulating disodium edetate.

In view of these results, it is considered that Gatifloxacin is colored by the metal ion dissolved in the preparation from the stainless steel beaker. Further, these results show that addition of disodium edetate can prevent coloration of Gatifloxacin.

Table 4 Concentration of Color Difference disodium edetate Stainless Steel Glass Beaker M Beaker 0 3.17 1.90 0.001 3.08 1.93 0.005 3.05 2.02 0.01 2.42 1.94 0.05 2.19 1.93 Example 1 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.5 g Disodium edetate 0.1 g Sodium chloride 0.9 g Hydrochloric acid q.s.
Sodium hydroxide q.s.

Sterilized purified water up to 100 ml pH 7.0 Example 2 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.5 g Disodium edetate 0.05 g Sodium chloride 0.9 g Hydrochloric acid q.s.
Sodium hydroxide q.s.
sterilized purified water up to 100 ml pH 7.0 Example 3 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.5 g Disodium edetate 0.1 g Sodium dihydrogen phosphate 0.1 g Sodium chloride 0.9 g Hydrochloric acid q.s.

Sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 7.0 Example 4 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.3 g Disodium edetate 0.05 g Sodium chloride 0.9 g Hydrochloric acid q.s.
Sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 6.0 Example 5 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.5 g Sodium edetate 0.01 g Glycerin 2.6 g Benzalkonium chloride 0.005 g Hydrochloric acid q.s.
Sodium hydroxide q.s..
Sterilized purified water up to 100 ml pH 7.5 Example 6 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.5 g Sodium edetate 0.05 g Sodium chloride 0.9 g Hydrochloric acid q.s.
Sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 5.5 Example 7 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following 5 formulation was prepared.

Ingredients Amount Gatifloxacin 0.3 g Disodium edetate 0.05 g Sodium chloride 0.9 g 10 Hydroxypropylmethyl cellulose 0.1 g Methyl p-hydroxybenzoate 0.026 g Propyl p-hydroxybenzoate 0.014 g Hydrochloric acid q.s.
Sodium hydroxide q.s.
15 Sterilized purified water up to 100 ml pH 6.0 Example 8 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.5 g Disodium edetate 0.01 g Sodium chloride 0.83 g Benzalkonium chloride 0.005 g Hydrochloric acid q,s.
Sodium hydroxide q,s.
Sterilized purified water up to 100 ml pH 5.5 Example 9 According to a conventional method, an aqueous solution for eye drops, ear drops and nasal drops having the following formulation was prepared.

Ingredients Amount Gatifloxacin 0.3.g Disodium edetate 0.01 g Sodium chloride 0.86 g Benzalkonium chloride 0.005 g Hydrochloric acid q.s.
Sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 6.0 As shown in Experiment 1, according to the eye drops of the present invention, corneal permeability of the effective component, Gatifloxacin, can be improved even by using disodium edetate in 1/10 amount as much as that normally used. Further, as shown in Experiment 2, the aqueous liquid preparation of the present invention can prevent precipitation of Gatifloxacin crystals under storage conditions as a low temperature.
Furthermore, as shown in Experiment 3, coloration of Gatifloxacin by a metal ion can be prevented. Thus, the aqueous liquid preparation of the present invention is very useful.

Claims (10)

1. An aqueous liquid pharmaceutical composition which comprises Gatifloxacin or its salt and disodium edetate.
2. The aqueous liquid pharmaceutical composition according to claim 1, wherein pH of the composition is within the range of 5 to 8.
3. The aqueous liquid pharmaceutical composition according to claim 1 or 2, where the composition is in the form of eye drops.
4. The aqueous liquid pharmaceutical composition according to claim 1 or 2, where the composition is in the form of ear drops.
5. The aqueous liquid pharmaceutical composition according to claim 1 or 2, where the composition is in the form of nasal drops.
6. A method for raising - corneal permeability of Gatifloxacin which comprises incorporating disodium edetate into eye drops containing Gatifloxacin or its salt.
7. A method for preventing precipitation of Gatifloxacin crystals which comprises incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
8. A method for preventing coloration of Gatifloxacin which comprises incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
9. The aqueous liquid composition according to any one of claims 1 to 5, wherein Gatifloxacin or its pharmaceutically acceptable salt is contained in an amount of 0.1 to 1.0 w/v% and disodium edetate is contained in an amount of 0.001 to 0.2 w/v%.
10. The aqueous liquid composition according to claim 9, wherein the amount of disodium edetate is 0.01 to 0.1 w/v%.
CA002307632A 1998-08-21 1999-08-20 Aqueous liquid pharmaceutical composition Expired - Lifetime CA2307632C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP235432/1998 1998-08-21
JP23543298 1998-08-21
PCT/JP1999/004483 WO2000010570A1 (en) 1998-08-21 1999-08-20 Aqueous liquid preparations

Publications (2)

Publication Number Publication Date
CA2307632A1 CA2307632A1 (en) 2000-03-02
CA2307632C true CA2307632C (en) 2007-05-22

Family

ID=16986030

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307632A Expired - Lifetime CA2307632C (en) 1998-08-21 1999-08-20 Aqueous liquid pharmaceutical composition

Country Status (16)

Country Link
US (1) US6333045B1 (en)
EP (1) EP1025846B1 (en)
JP (1) JP5138128B2 (en)
KR (1) KR100595956B1 (en)
CN (1) CN1133432C (en)
AT (1) ATE332692T1 (en)
AU (1) AU761040B2 (en)
BR (1) BRPI9906735B8 (en)
CA (1) CA2307632C (en)
DE (1) DE69932313T2 (en)
DK (1) DK1025846T3 (en)
ES (1) ES2264266T3 (en)
NZ (1) NZ504017A (en)
PT (1) PT1025846E (en)
TW (1) TW537895B (en)
WO (1) WO2000010570A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
BRPI0014470B1 (en) 1999-10-08 2016-08-23 Affinium Pharm Inc fab i inhibitor compounds, pharmaceutical composition, compound preparation process and use of the compounds for the manufacture of medicaments for treating bacterial infections
AU2001230525A1 (en) 2000-02-01 2001-08-14 Kyorin Pharmaceutical Co. Ltd. Sulfate salt of quinolonecarboxylic acid derivative and use thereof
CA2444597A1 (en) 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
EP1390073A2 (en) * 2001-05-03 2004-02-25 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
JP4859460B2 (en) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． Heterocyclic compounds, methods for their preparation and their use in therapy
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
JP2005008625A (en) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd Eye lotion containing quinolone-based antibacterial compound
CA2568914C (en) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US8476319B2 (en) 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
US20100041623A1 (en) * 2006-10-12 2010-02-18 Shirou Sawa Aqueous liquid preparation comprising gatifloxacin
CN101547695B (en) * 2006-10-12 2011-04-27 杏林制药株式会社 Aqueous liquid preparation having improved intraocular gatifloxacin penetration
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa Salts, prodrugs and polymorphs of fab i inhibitors
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
JP2008247828A (en) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd An aqueous pharmaceutical composition containing latanoprost.
JP5258331B2 (en) * 2008-03-03 2013-08-07 ロート製薬株式会社 Pharmaceutical composition containing a new quinolone antibacterial agent with improved photostability
KR20110017844A (en) 2008-03-31 2011-02-22 교린 세이야꾸 가부시키 가이샤 Aqueous solution containing gatifloxacin
CN102046173B (en) * 2008-03-31 2013-03-27 杏林制药株式会社 Aqueous liquid containing gatifloxacin, method for production thereof, and method for prevention of production of precipitates during storage of the aqueous liquid at low temperature or upon freezing/thawing of the aqueous liquid
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
BRPI0920026B1 (en) 2008-10-07 2023-11-07 Horizon Orphan Llc PHARMACEUTICAL COMPOSITION AND RESPECTIVE USES
CA2752296C (en) * 2009-02-18 2018-09-11 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
UA92423C2 (en) * 2009-07-24 2010-10-25 Анатолій Альбертович Кузьмін Antibacterial composition
PT2473170T (en) 2009-09-04 2019-08-23 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
AU2013241507A1 (en) 2012-03-26 2014-10-09 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
SI2861608T1 (en) 2012-06-19 2019-08-30 Debiopharm International Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
TN2018000293A1 (en) 2016-02-26 2020-01-16 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
JP6886322B2 (en) * 2016-03-25 2021-06-16 興和株式会社 Ophthalmic composition
SG11201901137UA (en) 2016-08-12 2019-03-28 Silk Technologies Ltd Silk-derived protein for treating inflammation
MY203711A (en) 2019-02-14 2024-07-15 Debiopharm Int Sa Afabicin formulation, method for making the same and uses thereof
JP7599838B2 (en) * 2019-04-10 2024-12-16 参天製薬株式会社 Aqueous pharmaceutical composition containing epinastine or a salt thereof
WO2020249731A1 (en) 2019-06-14 2020-12-17 Debiopharm International S.A. Afabicin for use for treating bacterial infections involving biofilm
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11510930B2 (en) 2020-08-26 2022-11-29 Somerset Therapeutics, Llc Gatifloxacin, prednisolone, and bromfenac compositions and methods
US11523987B2 (en) 2020-08-26 2022-12-13 Somerset Therapeutics, Llc Trimcinolone and moxifloxacin methods
US12016855B2 (en) 2020-08-26 2024-06-25 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU553415B2 (en) * 1983-09-19 1986-07-17 Abbott Japan Co., Ltd. 6-fluoro-1-4-dihydro-4-oxo-7-substituted piperazinyl- quinoline-3-carboxylic acids
JPH089597B2 (en) * 1986-01-21 1996-01-31 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid excellent in selective toxicity and its salt, and method for producing the same
JPH0696533B2 (en) 1987-01-14 1994-11-30 北陸製薬株式会社 Aqueous composition of quinolonecarboxylic acid
JP2549285B2 (en) * 1987-02-02 1996-10-30 第一製薬株式会社 Nasal spray
JPH01258620A (en) * 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd Local pharmaceutical for otopathy
JP3996659B2 (en) * 1995-10-25 2007-10-24 千寿製薬株式会社 Angiogenesis inhibitor
JPH09124484A (en) * 1995-10-27 1997-05-13 Schering Purau Kk Eye drops
AU5342498A (en) * 1997-01-10 1998-08-03 Wakamoto Pharmaceutical Co., Ltd. Difluprednate-containing ophthalmic o/w emulsion composition

Also Published As

Publication number Publication date
CN1133432C (en) 2004-01-07
NZ504017A (en) 2001-09-28
BRPI9906735B8 (en) 2021-05-25
WO2000010570A1 (en) 2000-03-02
TW537895B (en) 2003-06-21
US6333045B1 (en) 2001-12-25
KR100595956B1 (en) 2006-07-03
CA2307632A1 (en) 2000-03-02
CN1275081A (en) 2000-11-29
DE69932313T2 (en) 2007-07-19
DK1025846T3 (en) 2006-11-06
KR20010031240A (en) 2001-04-16
HK1029934A1 (en) 2001-04-20
PT1025846E (en) 2006-10-31
EP1025846A4 (en) 2004-12-29
AU5302699A (en) 2000-03-14
ATE332692T1 (en) 2006-08-15
BR9906735A (en) 2000-08-15
ES2264266T3 (en) 2006-12-16
JP5138128B2 (en) 2013-02-06
DE69932313D1 (en) 2006-08-24
EP1025846B1 (en) 2006-07-12
BRPI9906735B1 (en) 2015-09-01
AU761040B2 (en) 2003-05-29
EP1025846A1 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
CA2307632C (en) Aqueous liquid pharmaceutical composition
JPWO2000010570A1 (en) Water-based liquid
KR100276743B1 (en) Antiallergic composition for use on the eyes or nose
EP2785328B1 (en) Novel slow-releasing ophthalmic compositions comprising povidone iodine
EP0711546A1 (en) Ophtalmic solution based on diclofenac and tobramicine and its applications
WO1993024121A1 (en) Remedy for glaucoma
KR101587056B1 (en) Pharmaceutical compositios containing a fluoroquinolone antibiotic drug
US20100041623A1 (en) Aqueous liquid preparation comprising gatifloxacin
EP0604570B1 (en) Compositions containing quinolone antibiotics and sulfonate of polystyrol
US20090209599A1 (en) Eye drop containing roflumilast
US20100035894A1 (en) Aqueous liquid preparation having improved intraocular gatifloxacin penetration
JP3876232B2 (en) Ophthalmic preparations, eye drops, artificial tears, contact lens care products, eye washes, and eye ointments
JPH01294620A (en) Aqueous liquid preparation and production thereof
US20090247543A1 (en) Gatifloxacin-containing aqueous liquid preparation
JPH03109326A (en) Fleroxacin eye drop
HK1029934B (en) Aqueous liquid preparations
MXPA00003859A (en) Aqueous liquid preparations
US20090247752A1 (en) Gatifloxacin-containing aqueous liquid preparation, its production and method for suppressing formation of precipitate during storage at lower temperature and at the time of freezing and thawing of the aqueous liquid preparation
SA90110074B1 (en) Pharmaceutical compositions containing an aqueous solution of a pyranoquinoline derivative
TW304879B (en)
JPWO2002040028A1 (en) Antibacterial gel eye drops
KR20230145458A (en) Aqueous pharmaceutical composition containing ursodeoxycholic acid or its salt
CN115444849A (en) Ophthalmic pharmaceutical composition with improved preservative efficacy or photostability
CN117959251A (en) Recombinant human interferon α1b eye drops and preparation method thereof
WO2023218472A1 (en) An aqueous ophthalmic solution of nsaids and fluoroquinolone antibiotic and process of preparation thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190820